The delivery of this toxin to HER2+ cancer cells or xenograft tumors in future formulations with antibody-drug conjugates or nanoparticles may lead to improved treatments for metastatic cancer. This evidence concerns the gene ERBB2 and metastatic malignant neoplasm.